Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

Glomerulonephritis (GN) is an important cause of morbidity and mortality in patients of all
ages throughout the world. Because these disorders are relatively rare, it is difficult to …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis
(BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients …

In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60 …

Objectives To develop recommendations for the management of adult and paediatric lupus
nephritis (LN). Methods The available evidence was systematically reviewed using the …

Objective To evaluate the efficacy and safety of rituximab in a randomized, double‐blind,
placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with …

Objectives Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus
(SLE). All current treatment regimens include oral steroids, which are associated with severe …

Objective To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for
the initial therapy of lupus nephritis (LN). Study design This is an open randomised …

Lupus nephritis remains one of the most severe manifestations of systemic lupus
erythematosus associated with considerable morbidity and mortality. A better understanding …